152 related articles for article (PubMed ID: 17254767)
1. Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: Data mining of the NCI-DTP data sets and validation with human tumour xenografts.
Kobunai T; Ooyama A; Sasaki S; Wierzba K; Takechi T; Fukushima M; Watanabe T; Nagawa H
Eur J Cancer; 2007 Mar; 43(4):791-8. PubMed ID: 17254767
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice.
Ishikawa Y; Kubota T; Otani Y; Watanabe M; Teramoto T; Kumai K; Kitajima M; Takechi T; Okabe H; Fukushima M
Clin Cancer Res; 1999 Apr; 5(4):883-9. PubMed ID: 10213225
[TBL] [Abstract][Full Text] [Related]
3. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Kakimoto M; Uetake H; Osanai T; Shirota Y; Takagi Y; Takeshita E; Toriya Y; Danenberg K; Danenberg PV; Sugihara K
Cancer Lett; 2005 Jun; 223(1):103-11. PubMed ID: 15890242
[TBL] [Abstract][Full Text] [Related]
4. Dihydropyrimidine dehydrogenase activity correlates with fluorouracil sensitivity in breast cancer.
Yu Z; Yang Q; Sun J; Zhen J
Exp Oncol; 2007 Sep; 29(3):192-6. PubMed ID: 18004243
[TBL] [Abstract][Full Text] [Related]
5. Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Inoue T; Hibi K; Nakayama G; Komatsu Y; Fukuoka T; Kodera Y; Ito K; Akiyama S; Nakao A
J Gastroenterol; 2005 Feb; 40(2):143-7. PubMed ID: 15770397
[TBL] [Abstract][Full Text] [Related]
6. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
Fakhrejahani E; Miyamoto A; Tanigawa N
Cancer Chemother Pharmacol; 2007 Aug; 60(3):437-46. PubMed ID: 17377791
[TBL] [Abstract][Full Text] [Related]
7. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
8. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis.
Fukui Y; Oka T; Nagayama S; Danenberg PV; Danenberg KD; Fukushima M
Int J Mol Med; 2008 Dec; 22(6):709-16. PubMed ID: 19020767
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
11. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
12. The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
Li LH; Dong H; Zhao F; Tang J; Chen X; Ding J; Men HT; Luo WX; Du Y; Ge J; Tan BX; Cao D; Liu JY
Eur J Cancer; 2013 May; 49(7):1752-60. PubMed ID: 23313143
[TBL] [Abstract][Full Text] [Related]
13. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
14. [Application of non-steroidal anti-inflammatory drugs to enhance 5-fluorouracil efficacy in experimental systems].
Réti A
Magy Onkol; 2010 Dec; 54(4):377-81. PubMed ID: 21163769
[TBL] [Abstract][Full Text] [Related]
15. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I
Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
17. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy.
Tateishi Y; Tatemoto Y; Ohno S; Morishita K; Ueta E; Yamamoto T
Cancer Lett; 2009 Feb; 274(2):187-93. PubMed ID: 18986760
[TBL] [Abstract][Full Text] [Related]
18. Sequence analysis of the 5'-flanking regions of human dihydropyrimidine dehydrogenase gene: identification of a new polymorphism related with effects of 5-fluorouracil.
Hasegawa T; Kim HS; Fukushima M; Wataya Y
Nucleosides Nucleotides Nucleic Acids; 2005; 24(4):233-42. PubMed ID: 16021908
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
20. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
Amstutz U; Farese S; Aebi S; Largiadèr CR
J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
